Groups
Main Sector
Investor Type
Service Provider Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Index
Countries
Reset

Antibody Solutions United States

Antibody Solutions is a premier developer of therapeutic, diagnostic and critical reagent antibodies. Our platforms include human antibodies from transgenic OmniRats™, Hybridoma Libraries™, and high-throughput flow-cytometry screening of cell-associated targets. We provide full technical support and project management with all services performed in the USA. 

Website:
www.antibody.com
Year Founded
1995
Service Provider Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Unique Capabilities

Human Ab producing OmniRats™ 

Hybridoma Libraries™  

High-throughput flow-cytometry screening 

Proven record of success

In Vitro Ab Production

Proven track record of success

John Kenney
President 

Apple Tree Partners United States

Apple Tree Partners is a private equity fund that was established in 1999 and based in New York, NY, with satellite offices in Princeton, NJ, Cambridge, MA and Brussels, Belgium. The firm controls up to $1.75 billion in assets under management and makes equity investments ranging from $100,000 for academic spinouts to $150 million dollar in later stage deals. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.

Website:
http://www.appletreepartners.com
Year Founded
1999
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Sam Hall
Principal 
Aaron Kantoff
Vice President 

Artery Therapeutics Inc. United States

Artery Therapeutics is a San Francisco Bay Area based translational biotechnology company with worldwide collaborations. Artery's novel peptide library derived from Apolipoprotein E shows promising results in various animal studies for diseases such as Alzheimer's disease, Diabetes mellitus, and Acute Coronary Syndrome.

Website:
www.arterytx.com
Year Founded
2004
Main Sector
Biotech Subsector
Indication
Biotech Phase of Development
Technology Overview

Licensed peptide technologies from University of California, Berkeley, i.e. ApoE Derived ABCA1 Agonists with athero-protective, anti-diabetic actions and effects on ApoE4 associated Alzheimer’s Disease. The lead ABCA1 agonists are non-toxic, drugable candidate drugs ready to enter into IND enabling studies for phase 1 and proof of concept testing in man.

Alliance & Collaborations
Currently no Alliances or Corporate Collaborations. ARTERY has entered into several material transfer agreements with BigPharma potentially leading to collaboration deals or other deals.
Supporting Metrics or Evidence

Cogpep for Alzheimer’s Disease and Traumatic Brain Injury 90% reduction of P-Tau, 55% reduction in Amyloidb42, Increase Vglut1, apoER2, short term and long term cognition. Dipep shows antidiabetic actions (glucose reducing and insulin sensitizing) and anti-atherosclerosis effects without creating hypoglycemia. Stabilization and regression of atherosclerosis (25-40%) Weight neutral & preservation of β-cell function Lowers HbA1C

Current Financing Needs

Artery is seeking a committed pharma partner to move technology to market and beyond. Or $16M to move technology into IND enabling studies for phase 1 and proof of concept testing in man.

Current Timeline

Both Cogpep and Dipep are candidate drugs and can be in the clinic within 12 months

Current Investors

F&F

IP Status

7 cases, 37 patents, 5 issued,

Recent Milestones

Animal proof of concept studies in diabetes and Alzheimer’s disease, Has secured multiple MTA with Big Pharma Additional composition of matter patents has been filed

Management Team Highlights

Jan Johansson MD, PhD is a serial Biotech entrepreneur and has as founder and/or corporate officer helped take 3 companies’ public and raised more than $400M in private and public markets. Jan is trained as a basic scientist, practiced cardiovascular medicine for 18 years and has translational and development background with particular reference to cardiovascular technologies. Jan has lead basic research groups and lead clinical phase 1-3 programs. Jan is the inventor of more than 40 patents

Mr Jonas Johansson
Mr Jonas Johansson
Co-Founder 

Artiman Ventures

Artiman is a venture capital company founded in 2 and based in Palo Alto California. The firm is currently making investments out of its fourth $2 million fund. The firm makes seed and venture investments into firms ranging from a few hundred thousand to $5 million depending on the stage and financial requirements of the company. The firm has a preference for companies based in Silicon Valley but will consider opportunities globally and looks to make around 5 investments per year.
Website:
www.artiman.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Akhil Saklecha
Managing Director 

Asset Management Ventures

Asset Management Ventures is a private investment firm funded by a single LP and is based in California USA. The firm invests in seed and early-stage health technology companies. The typical investment size for seed investment ranges from $25K to $1M (usually in equity or convertible notes). For early-stage companies the firm typically co-invests with other VC firms in Series A and B financing and the investment size will depend on the company?s financial needs. The firm is geographically agnostic but prefers start-ups to be based on the West Coast. The firm is actively seeking new investment opportunities.
Website:
www.assetman.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Capital Structure Preference
Investment Stage Preference
Richard Simoni
Managing Partner 

ATEM Capital

ATEM Capital manages evergreen Life Sciences investment fund - Health Square Fund (HSF). HSF acts as a consolidator of capital flows from the Emerging Markets and invests into the biotech innovation hubs of the US/Western Europe. HSF's international team combines big-picture business perspective with decades of investment scientific legal portfolio risk management and operational experience. The fund is audited by a Big-4 firm. Our Advisory Board comprises high-caliber entrepreneurs VC veterans and seasoned Wall Street professionals.
Website:
www.atemcap.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Alexey Afanasiev
Executive Partner 
Anton Gopka
CEO General Partner 
Elena Ikhsanova
COO General Partner 

Baird Venture Partners

Baird Venture Partners is the venture and expansion capital arm of Robert W. Baird & Co. The Baird Venture Partners team is based in Chicago Illinois and has around $27 million in total assets under management. In 214 Baird closed a fourth venture capital fund at $185 million. The firm is currently seeking opportunities in the life science sector and while Baird has no strict timeline to make investments the group would invest in a new firm within the next 6-9 months if a compelling opportunity was identified. The firm?s equity investments range from $3-1 million but are typically in the $8-1 million range.The firm will only consider investment into US based firms.
Website:
www.rwbaird.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Momei Qu
Senior Associate 

Band of Angels

The Band of Angels is a funding organization that was founded in 1994 and it is based in Silicon Valley California. The organization typically provides capital to companies through three programs: The Band of Angels Acorn Fund and The Band of Angels Venture Fund. The group focuses on seed and Series A stage high-tech companies across several industries including life science space. The Band of Angels generally makes investments ranging from $3K to $75k but it often leads a syndication of $2-3million. Acorn Fund which is The Band?s third side fund and was founded in 29 generally makes investments ranging from $1k to $75k. The Band of Angels Venture Fund is a $5 million venture fund which raised in 1999 by The Band of Angels. Initial investment sizes of the fund are typically $3 and can go up to $2.5 million. The Band generally makes around 1 -2 investments per year. The group focuses on companies based in Silicon Valley but it will consider selective opportunities in Los Angles and San Diego areas. The group's portfolio includes biotechnology and medical device companies working with oncology and muscle recovery.
Website:
www.tosk.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Brian Frenzel
Member 
Michael Bates
Member, Board of Directors 

Baxter Ventures

Baxter Ventures is the strategic venture arm of Baxter International Inc. that was formed in 2011 and is based in Deerfield, Illinois. The firm is currently making equity investments out of a $200 Million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.

Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Priyanka Rohatgi
Director 

Becton Dickinson (BD)

BD (Becton Dickinson and Company) based in Franklin Lakes NJ is a leading medical technology company that partners with customers and stakeholders to address many of the world?s most pressing and evolving health needs. Their innovative solutions are focused on improving drug delivery enhancing the diagnosis of infectious diseases and cancers supporting the management of diabetes and advancing cellular research. The firm has nearly 3 associates in 5 countries who strive to fulfill our purpose of ?Helping all people live healthy lives? by advancing the quality accessibility safety and affordability of healthcare around the world. For more information please visit www.bd.com. BD partners with companies from their formation through to commercialization including expansion of operations and channel access. BD considers a variety of engagement models including research collaborations licenses investments and acquisition when partnering with companies aligned with BD?s core businesses and new areas of strategic interest seeking opportunities from around the globe.
Website:
www.bd.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Albert Lauritano
Director Strategic Technology Partnerships